Pyxis Oncology to present MICVO Phase 1 data in head and neck cancer
PYXS•Pyxis Oncology will present Phase 1 micvotabart pelidotin monotherapy data in previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma on Nov. 19, 2026, in Barcelona.
1. Presentation schedule
Pyxis Oncology will present the data at the EORTC-NCI-AACR symposium. Two preclinical posters are scheduled for Nov. 18, including findings that micvotabart pelidotin combined with EGFR-targeted therapy produced longer responses in models.
